---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-083676"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:54:48.772253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FibroGen shareholders approve reverse stock split; appoints Michael Kauffman to board

## Summary
- Shareholders approved reverse stock split (1:10-1:25) to meet Nasdaq listing requirement; 85% voted in favor.
- Jeffrey L. Edwards re-elected as Class II director with 92.25% of votes cast.
- Dr. Michael Kauffman appointed to board, will serve on Audit and Compensation Committees; term expires 2026.
- Director Aoife Brennan resigned effective June 4, 2025, no disagreement with company.
- Second amendment to financing agreement lowered minimum cash balance from $27M to $22.5M.

## SEC filing metadata
- accession: 0000950170-25-083676
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 5.02, 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/fgen-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-083676
- JSON: https://secwatch.observer/filing/0000950170-25-083676.json
- Plain text: https://secwatch.observer/filing/0000950170-25-083676.txt

## Key facts
- Executive change
  Aoife Brennan resigned as Director at KYNTRA BIO, INC..
  - Action: resigned
  - Role: Director
  source text: On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the “Board”) notification of her resignation from the Board of FibroGen, effective June 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm
- Executive change
  Michael Kauffman was appointed as Class III director at KYNTRA BIO, INC..
  - Action: appointed
  - Role: Class III director
  source text: Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017025083676/0000950170-25-083676-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.